2024 CMR GLOBAL CLINICAL PERFORMANCE METRICS PROGRAMME

Clarivate™

INTRODUCTION

CMR international (CMR), a Clarivate business, is a leader in biopharmaceutical R&D performance analytics. For over 25 years, CMR has worked with the leading global biopharmaceutical companies to assess R&D productivity and provide actionable data and insights, strengthening R&D efficiency and effectiveness. In 2024, CMR will collaborate with biopharmaceutical companies by running the CMR Global Clinical programme and its associated modules, which collects metrics on all active substances and associated trials from protocol draft to clinical study report across all participating companies.

In response to the increasing need for truly innovative and differentiated drug products, ever increasing cost of development, regulatory and payer challenges, the biopharmaceutical industry is seeking new drug development strategies to maximise R&D productivity. The design and execution of efficient and effective clinical studies to support these new strategies is integral to managing costs and to support quality project and portfolio decision making.

The Global Clinical programme participants receive a range of reports, and online tools, which enable clients to customise metrics to their individual business contexts, supporting clinical trial planning and monitoring within these changing development models.

USING THE DATA WITH CONFIDENCE

CMR's performance analytics programmes have been the gold standard for collecting and reporting biopharmaceutical R&D performance metrics for over 25 years. Data are collected directly from participating companies, validated and combined into a large, blinded reporting database. Containing data on approximately 9,000 active substances, over 25,000 clinical trials, over a 100,000 country records and 500,000 hospital site records; the Global Clinical programme database has the breadth and depth to inform your strategic decision making, support clinical operations and country selection and address your clinical key business questions.

METRICS CAPTURED IN THE CLINICAL PROGRAMME

- Trial cycle times (Protocol draft to Clinical study report)
- Country cycle times
- Site metrics
- Enrolment metrics
- Clinical trial costs
- Protocol amendments
- Protocol complexity
- Trial quality indicators
- Country selection and performance

COUNTRY SELECTION

With the continuing globalisation of clinical research, the value of identifying superior performing countries and sites is becoming increasingly invaluable.

Utilising our online tools, participants can interrogate data to improve their understanding of clinical performance across countries and regions (Figure 1).

FIGURE 1: START-UP TIME BY REGION



PROTOCOL AMENDMENTS

Since 2012, CMR has been running a focused protocol amendments module which collects detailed information on global protocol amendments. This data enables CMR to quantify amendments as well as the nature and reason for amendments. Additionally, CMR can provide correlations between time, enrolment and cost to assess the impact of amendments.

CLINICAL COST

Since 2010, CMR has been collecting direct costs for completed clinical trials. The dataset includes direct cost figures for over 4000 records and this data helps CMR to produce more robust clinical productivity measures such as cost per patient per trial and provide correlations between time, cost and quality.

FIGURE 2: COST PER SUBJECT TREATED (PHASE III)



FIGURE 3: CLINICAL PROGRAMME SCOPE

Trial efficiency
- Trial start up, enrolment, treatment and close-out
- Outsourcing trends within trials
- Enrolment, Screen failure and Drop-out rates
- Number of countries and sites initiated
- Number, timing and reason for protocol amendments

Cost per trial
- Cost per completed trials
- FTE costs per completed trials
- Non-FTE costs per completed trials
- Cost per subject

CMR Clinical Metrics

Country selection and performance
- Country start-up and enrolment
- Regulatory and IRB approval cycle times
- Enrolment and Screen failure rates
- Number of sites initiated

Site selection and performance
- Site selection, contracting, initiation, enrolment and treatment cycle time
- First site to 25th, 50th ,75th and 90th site initiated
- Low Performing Sites
- Enrolment and Treatment rates

FIGURE 4: ILLUSTRATIVE OF CMR TOOLS (CiMoR) AND REPORTS

Global Clinical programme participants receive a range of online tools (CiMoR), which enable clients to customise metrics to their individual business contexts, supporting clinical planning and country selection decision making within today's biopharmaceutical industry. Utilising our online tools, participants can interrogate data to improve their understanding of operational drivers of key metrics such as cycle times and operational efficiency (Figure 4).



UNDERSTAND THE DETAILS

If you have any questions relating to this specific or any other CMR programmes, please do contact Jasmin Mehta (jasmin.mehta@clarivate.com) or Beth Deane (beth.deane@clarivate.com). We can demonstrate our on-line CiMoR tools, discuss detailed programme content or focus on your specific business needs and questions.